Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity
about
sameAs
Disruption of a GATA4/Ankrd1 signaling axis in cardiomyocytes leads to sarcomere disarray: implications for anthracycline cardiomyopathyThe HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyCardiac toxicity of trastuzumab in elderly patients with breast cancerThe Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer TherapyExercise Prevention of Cardiovascular Disease in Breast Cancer SurvivorsTissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screeningCancer survivors in the United States: a review of the literature and a call to actionNeuregulin as a heart failure therapy and mediator of reverse remodelingNeuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclinesRecent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsHeat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytesActivation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy.Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.Actin binding GFP allows 4D in vivo imaging of myofilament dynamics in the zebrafish heart and the identification of Erbb2 signaling as a remodeling factor of myofibril architecture.Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure.Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological preventionNeuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury.The transcriptomic profile of peripheral blood nuclear cells in dogs with heart failurePooled analysis of cardiac safety in patients with cancer treated with pertuzumab.Practical Management Recommendations for Anti-ErbB2 Therapy with Lapatinib.Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?Targeting HER2 in breast cancer: overview of long-term experienceCardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experience.ErbB signaling in cardiac development and disease.Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes.Intravenous glial growth factor 2 (GGF2) isoform of neuregulin-1β improves left ventricular function, gene and protein expression in rats after myocardial infarction.Anthracycline cardiotoxicity: prevalence, pathogenesis and treatmentCardiac dysfunction after cancer treatment.Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice.Neuregulin-1β for the treatment of systolic heart failure.Trastuzumab-induced cardiac dysfunction: A 'dual-hit'Underuse of anthracyclines in women with HER-2+ advanced breast cancer.Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathwaysApoptosis in Anthracycline CardiomyopathyThe Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis.The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferationImprovement of cardiac function and reversal of gap junction remodeling by Neuregulin-1β in volume-overloaded rats with heart failure.Sodium nitroprusside induces cell death and cytoskeleton degradation in adult rat cardiomyocytes in vitro: implications for anthracycline-induced cardiotoxicity.Cardiac dysfunction associated with trastuzumab.Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials.
P2860
Q21134606-A31B2E3B-36A9-4430-BFE1-07F9A1BF82D2Q21284978-63E1060A-82C4-4C26-9360-7040E86EB17DQ26741182-60F64C6C-F3F9-4F6B-81B0-F5BC51A1D18AQ26743433-0FB05B54-7E48-4BA4-8CBC-B1D995F73C0DQ26785410-61838275-E515-4D88-A55D-9D64D9BFFAA8Q26799470-562A6BCF-8CF7-4E0E-80B0-6915322908DDQ26865247-3381B6EE-2CCC-4DEE-9BD8-DBE1A0D617F0Q26991903-730A70A3-714F-429D-84E9-AF7FCC0E9104Q27022965-5D0478D0-1041-4EB0-8D62-89D52F376CE3Q28087776-C204E318-327A-45FC-A733-DB0F657A812AQ28572341-BD9D8A61-BBF2-40AF-ABE5-67F27B69AE72Q29347286-5491903D-26EB-47A7-A4B9-A3BE7AD66892Q30593372-2CB9B405-E42C-4B22-ACBC-76FBAFC4E399Q30631200-3C97DC78-E871-470F-BF22-05C4D0C01D3AQ30663382-66AE829E-E89D-4BDF-A270-4C9D9B1EC156Q33574045-2B2216D5-4527-4C71-A894-7DEDE07323E6Q33822811-106EEF8C-3C9D-4636-A46B-4AC9E2B8C3ADQ33883059-883DE75E-3174-4812-8DE0-9CEB560E1BC1Q33930241-09515933-9AF5-42FC-8904-FDC49A29879EQ34095753-ABD75FFC-18CA-4515-9345-B8AA9A93E8A2Q34102834-AB34BB85-1B58-4C06-A162-13C7BC94064AQ34272044-33E6FCA6-8850-42B9-9767-55485B51777FQ34403544-879197F6-8F56-4912-B167-1DF2B99AE715Q34545577-7B093FC9-A6D2-41C0-8CC3-99C943FD7AF5Q34576324-CA375313-5533-4C6D-A328-D5F95B0AB65AQ34598168-EA641872-AF77-421F-9D7C-E473077F9736Q34639876-52A76C2C-722C-49CA-AD0A-9199B28F464EQ35039549-48F53C84-F29A-41A0-A4A9-22DC5E008347Q35047415-9EFA9537-0672-4987-BB8F-B6FAA6ABDF1DQ35231868-D61E417E-A828-4F9B-BED6-EB6162B33E7FQ35532125-8F78B18E-4D6D-4154-9B3A-5B64A3926A74Q35584166-D9E0A8DC-59FD-44A6-9DC3-1810C175BF8FQ35605824-64CB76D3-9DD9-487D-92DC-167DF6890D68Q35642302-8966553E-F574-45E0-BCBB-7A79FD6DDA88Q35948882-30D0F4E2-96C7-4279-81E8-9A8DA75DC03FQ36042588-439AE355-A0CF-437D-AE22-CEB042DA5894Q36163718-8FAA8312-4BAC-416C-BE85-0150F6E52CDBQ36193603-CDF45382-01D6-43BF-B134-5140B6F05643Q36565032-31DD0B23-ECAA-4B6E-B3AA-3C256438F721Q36569759-2DA75C77-ECB6-42A0-8F5F-F6F6AFEAE954
P2860
Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Modulation of anthracycline-in ...... tuzumab-induced cardiotoxicity
@ast
Modulation of anthracycline-in ...... tuzumab-induced cardiotoxicity
@en
Modulation of anthracycline-in ...... tuzumab-induced cardiotoxicity
@nl
type
label
Modulation of anthracycline-in ...... tuzumab-induced cardiotoxicity
@ast
Modulation of anthracycline-in ...... tuzumab-induced cardiotoxicity
@en
Modulation of anthracycline-in ...... tuzumab-induced cardiotoxicity
@nl
prefLabel
Modulation of anthracycline-in ...... tuzumab-induced cardiotoxicity
@ast
Modulation of anthracycline-in ...... tuzumab-induced cardiotoxicity
@en
Modulation of anthracycline-in ...... tuzumab-induced cardiotoxicity
@nl
P2093
P3181
P1433
P1476
Modulation of anthracycline-in ...... tuzumab-induced cardiotoxicity
@en
P2093
Christian Zuppinger
Douglas B Sawyer
Hans M Eppenberger
Thomas A Miller
Thomas M Suter
P304
P3181
P356
10.1161/01.CIR.0000013839.41224.1C
P407
P577
2002-04-02T00:00:00Z